DRC Ebola response leaves 5,608 daily contact checks unrecorded

The Democratic Republic of the Congo's Ebola response recorded 38,538 contacts requiring follow-up, but health teams saw only 32,930 during the latest reporting day. The difference is 5,608 people whose daily observation was not recorded, a more useful measure of the response's immediate blind spot than the national case total alone.

Those figures appear in the Congolese public-health institute's October 27 situation report, published October 28. The European Centre for Disease Prevention and Control incorporated that reporting cutoff into its October 29 update: 10,193 confirmed cases and 4,960 related deaths. These are reported cumulative totals through October 27, not a count of infections acquired on October 29.

The distinction matters for employers transporting staff, clinics buying protective supplies and organizations arranging care across borders. A headline count measures the outbreak already identified. Daily follow-up measures part of the system meant to find the next case before it exposes someone else.

The shortfall behind an improving percentage

Daily contact follow-up reached 85.4%, up from the previous report's 84.5%. That is an improvement, but it remains below the 95% operational threshold in the national report and WHO's October 23 outbreak assessment.

Calculated from the latest denominator, reaching at least 95% would require 36,612 observations. Against 32,930 recorded, that means 3,682 additional checks in a day, assuming the contact list stayed unchanged. It is a workload calculation, not a forecast of how many infections those checks would prevent.

The missing observations also do not mean 5,608 infected people were circulating. Contacts are people identified for monitoring, not confirmed cases. Nor does a missed daily observation establish that a person could not be reached at any other time. Confusing those categories would exaggerate what the surveillance data show.

There is a second limit: the denominator contains known contacts. Better performance on that list would not prove that every exposed person had been identified. The indicator can improve while a separate gap in finding contacts remains.

The national average conceals different operating conditions

The primary report puts daily follow-up at 99.0% in Bas-Uélé, 91.5% in Ituri, 85.1% in Haut-Uélé, 82.6% in Nord-Kivu and 44.5% in Tshopo. Its operational sections describe transport problems, insecurity and incomplete reporting. The uneven figures argue against treating the response as one nationally uniform service.

That makes deployment decisions more specific than simply adding an equal number of workers everywhere. A province with an observation gap may need transport, communications or access as well as personnel. The report is evidence of those constraints, not enough information to rank the cost-effectiveness of individual interventions.

The practical question for an organization operating locally is whether it can obtain reliable, location-specific arrangements for assessment and transport. A national surveillance percentage cannot answer that question on behalf of a clinic or a field team. Neither does it establish that commercial travel across an entire country has stopped.

A high death ratio is not a personal prognosis

The latest cumulative totals imply a crude death-to-confirmed-case ratio of approximately 48.7%, consistent with the national report. That ratio describes reported outcomes across the outbreak; it is not a prediction that any newly diagnosed individual has exactly that chance of dying.

WHO's earlier assessment highlights deaths in communities and difficulty obtaining timely care. Its transmission explanation is also specific: infection spreads through direct contact with infected bodily fluids or contaminated materials, with particular risks in inadequate health-care infection control and unsafe burials. WHO says people become infectious after symptoms begin.

That mechanism is why the follow-up gap deserves attention. Monitoring can help connect symptom recognition to assessment and care. It does not substitute for protective equipment, safe clinical practice or laboratory confirmation, and this analysis does not establish how many of the latest deaths would have been avoidable.

The vaccine trial does not close today's protection gap

A separate development offers a research route rather than a completed solution. CEPI says the first participant in the Tumaini Phase 2/3 trial was vaccinated in Bunia on October 23. The platform starts with Ervebo, a vaccine licensed against Ebola virus, while evaluating protection against the different Bundibugyo virus responsible for this outbreak.

There is no approved Bundibugyo vaccine. A product's existing approval for one virus cannot be turned into proof of efficacy against another. The trial is designed to establish safety, immune response and protection, using ring vaccination focused on high-risk contacts. Preparations for other candidates do not mean those candidates have already produced trial results.

CEPI also describes Gavi's commitment of up to $40 million for manufacturing readiness. That is conditional capacity preparation, not proof that an effective vaccine is available today. The business distinction is between financing readiness and having an approved product ready for ordinary procurement.

Cross-border readiness is different from blanket restrictions

The international picture requires the same separation of categories. ECDC's October 29 update records 62 identified contacts under follow-up in Nigeria as of October 27, following its imported case. An expanded contact list is not an expanded confirmed-case count.

WHO's October 23 advice opposed travel and trade restrictions with affected countries while calling for surveillance and coordinated preparedness. That combination supports targeted readiness rather than reading the outbreak total as evidence for an indiscriminate shutdown. It does not guarantee an uninterrupted itinerary or override a particular government's entry requirements.

The next check is the next dated national situation report. It should be compared on its reporting cutoff, contact denominator, observations completed and newly reported cases, rather than its webpage publication date alone. No fixed release time or trial-results date was established in the documents reviewed. The October 29 update shows improvement in one surveillance measure; it does not yet demonstrate that transmission is controlled.

Sources: DRC INSP Situation Report 166; ECDC's October 29 update; WHO's October 23 Disease Outbreak News; CEPI's Tumaini trial announcement. Contact shortfalls and the threshold workload are Chronicle calculations. This is public-health reporting, not individual medical advice.